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Ca2+ signaling through CaMKII is critical in regulating myocyte function with regard to excitation–contraction–relaxation cycles and
excitation–transcription coupling. To investigate the role of nuclear CaMKII in cardiac function, transgenic mice were designed and generated to
target the expression of a CaMKII inhibitory peptide, AIP (KKALRRQEAVDAL), to the nucleus. The transgenic construct consists of the murine
α-myosin heavy chain promoter followed by the expression unit containing nucleotides encoding a four repeat concatemer of AIP (AIP4) and a
nuclear localization signal (NLS). Western blot and immunohistochemical analyses demonstrate that AIP4 is expressed only in the nucleus of
cardiac myocytes of the transgenic mice (NLS-AIP4). The function of cytoplasmic CaMKII is not affected by the expression of AIP4 in the
nucleus. Inhibition of nuclear CaMKII activity resulted in reduced translocation of HDAC5 from nucleus to cytoplasm in NLS-AIP4 mouse hearts.
Loss of nuclear CaMKII activity causes NLS-AIP4 mice to have smaller hearts than their nontransgenic littermates. Transcription factors including
CREB and NFκB are not regulated by cardiac nuclear CaMKII. With physiological stresses such as pregnancy or aging (8 months), NLS-AIP4
mice develop hypertrophy symptoms including enlarged atria, systemic edema, sedentariness, and morbidity. RT-PCR analyses revealed that the
hypertrophic marker genes, such as ANF and β-myosin heavy chain, were upregulated in pregnancy stressed mice. Our results suggest that
absence of adequate Ca2+ signaling through nuclear CaMKII regulated pathways leads to development of cardiac disease.
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each having defined functions related to excitation, contraction,
relaxation, metabolism and gene transcription. Ca2+ is a primary
regulator of cardiomyocyte function and its transitory levels are
precisely controlled in subcellular compartments including the
longitudinal SR, junctional SR, sarcolemma and nucleus. A
major sensor and mediator of the intracellular Ca2+ transients is
calmodulin (CaM). The Ca2+–CaM complex binds and acti-
vates target proteins such as kinases, phosphatases and
channels. Ca2+–CaM dependent kinase II (CaMKII), a major
CaM target protein, is a uniquely regulated multifunctional
regulatory enzyme. CaMKII “autophosphorylation” causes the
enzyme to become autonomous to Ca2+–CaM and able to
record previous Ca2+ events including the frequency, amplitude
and duration of the Ca2+ transients. There are four isoforms of
CaMKII, α, β, γ and δ. The δ isoforms are the prominent
cardiac isoform. Two primary splice variants of CaMKIIδ, δB⁎ Corresponding author. Tel.: +1 513 558 4145; fax: +1 513 588 5061.
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doi:10.1016/j.bbamcr.2006.09.029and δC are identified [1]. The δB isoform contains a nuclear
localization signal and localizes to the nucleus; the δC isoform is
restricted to the cytoplasm [1]. Our hypothesis is that inhibition
of CaMKII at discrete Ca2+ cycling domains will modify
cardiomyocyte functional properties and allow the identification
of molecular pathways that lead to cardiomyopathy.
Autocamtide II, a 13-amino acid, is an ideal substrate for
CaMKII (Fig. 1A). Mutation of the phosphate accepting
threonine to alanine makes it an autocamtide inhibitor peptide
(AIP) (Fig. 1A). This short sequence has potent inhibitory
properties for CaMKII, 50-fold greater than the autoinhibitory
domain and 500-fold greater than KN-93. The inhibitory
mechanisms of KN-93 and AIP are distinct. KN-93 competes
with CaM in the activation of CaMKII; AIP binds the active
site. AIP does not affect cyclic AMP-dependent protein kinase,
protein kinase C, calmodulin-dependent protein kinase IV, and
other unidentified protein kinases occurring in extracts [2]. Ji et
al. [3,4] targeted AIP to the cardiac longitudinal sarcoplasmic
reticulum (SR) in transgenic mice using a truncated form of
phospholamban (PLN). The isolated myocytes had a reduced
Fig. 1. Assemble of the NLS-AIP4 transgenic construct. (A) Sequence of the
“idealized” CaMKII substrate (autocamtide II) and the inhibitory (AIP). (B) The
transgenic construct. Murine α-myosin heavy chain promoter (α-MHC)
followed by the expression unit containing nucleotides encoding a four repeat
concatemer of AIP, and a nuclear localization signal (NLS). (C) Plasmids
containing the AIP4 targeting constructs were transfected into BHK 21 cells.
After 48 h the cells were fixed with 4% formalin, permeabilized with acetone,
incubated with rabbit anti- AIP4 followed with fluorescein anti-rabbit IgG.
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period. These animals displayed reduced cardiac function and
developed hypertrophy and dilated myopathy as they aged or
were physiologically stressed.
It is well established that Ca2+ transients regulate transcrip-
tion and gene expression that characterize the hypertrophic
response of cardiomyocytes [5,6]. The mechanism by which
cardiomyocytes distinguish the Ca2+ transients that occur at
every heartbeat to initiate contractions from those directed to
regulate transcription has posed an enigma. There are several
independent mechanisms to create an intra-nuclear Ca2+ signal
[7]. Ca2+ transients created by E–C coupling may pass unres-
tricted through the pores of the nuclear membrane. In neurons,
Ca2+/CaM translocates from the cytosol into the nucleus and
activates target proteins such as CaMKII [8]. The nucleus,
however, is also capable of producing Ca2+ transients inde-
pendent of the sarcoplasm [9,10]. The nuclear membrane of
cardiomyocytes [11] and other cell types [12] contains inositol
1,4,5-trisphosphate receptors (IP3R) [13] demonstrating that the
nuclear envelope is capable of storing and releasing Ca2+.CaMKII plays a prominent role in coupling Ca2+ signals to
transcriptional events in cardiomyocytes. CaMKIIδB, the nuclear
targeted isoform, regulates several transcription factors and other
DNA-binding proteins including cAMP response element
binding protein, CREB [14], CAAT-enhancer binding protein,
C/EBP [15], activating transcription factor, ATF-1 [16], activator
protein 1, AP-1 [17], serum response factor, SRF [18], and
myocyte enhancer factor-2, MEF2 [19]. MEF2 may be a
common endpoint for hypertrophic signaling pathways in the
myocardium by interacting with class II histone deacetylases
(HDACs), a family of transcriptional repressors [20]. Wu et al.
[21] recently demonstrated that ET-1 activates nuclear CaMKII
via the activation of sarcolemma phospholipase to produce IP3.
IP3 enters the nucleus, binds nuclear envelope IP3Rs that locally
release Ca2+ and activate nuclear CaMKII. The kinase then
phosphorylates HDACwhich releases transcriptional repression
of MEF2. These findings demonstrate that myocyte [Ca]i is
segregated, the ICa/RyR2 Ca
2+ transient initiates contraction
without affecting nuclear events, whereas IP3 releases intra-
nuclear Ca2+ without affecting cytosolic events.
In order to investigate the role of nuclear CaMKII, transgenic
mice of expression AIP (NLS-AIP4) targeted to the nuclear were
generated. We demonstrate that inhibition of nuclear CaMKII
activity by AIP4 results in a decreased HDAC5 translocation
from nucleus to cytoplasm. The NLS-AIP4 mice have smaller
hearts than their nontransgenic littermates until 15–20 weeks of
age. Cardiac nuclear CaMKII does not phosphorylate CREB and
NFκB. Physiological stresses such as pregnancy or aging
(8 months) causes NLS-AIP4 mice to develop enlarged atria,
systemic edema, sedentariness, and morbidity. Our results sug-
gest that the inhibition of nuclear CaMKII regulated pathways
leads to development of cardiac disease.
1. Materials and experiment procedures
1.1. Chemicals and antibodies
Isoproterenol (ISO), endothelin-1 (ET-1), proteinase inhibitors, phosphotase
inhibitors, and other chemicals used in the experiments were purchased from
Sigma Chemical Co. (St. Louis, MO, USA). Anti-phospho-CREB (Ser133),
total-CREB, and phospho-NFκB p65 (Ser536) antibodies were obtained from
Cell Signaling (Beverly, MA, USA). Anti-phospholamban Thr17 and Ser16
were purchased from Badrilla Ltd. (Leeds, LS179WA, England). Anti-GAPDH
antibody was purchased from Calbiochem (La Jolla, CA, USA). Secondary
antibodies were purchased from BioRad (Hercules, CA, USA). The western
blotting chemiluminescence reagent kit was purchased from Amersham
Biosciences (Piscataway, NJ, USA).
1.2. Assemble of NLS-AIP4 construct
The transgenic construct was assembled as shown in Fig. 1B. The expression
unit contains nucleotides that encodes a AIP tetramer (AIP4), and an nuclear
localization signal (NLS) and SV40 polyadenylation signal. The NLS, pro–lys–
lys–arg–lys–val, has proven to be a very effective nuclear targeting motif since
its discovery [22]. Nuclear expression of NLS-AIP4 was tested in BHK21 cells
using CMV promoter to ensure the nuclear targeting of AIP before transgene was
assembled. As shown in Fig. 1C, AIP is highly concentrated in the nuclei of
BHK21 cells. Selective expression to cardiomyocytes was achieved using the
5.5-kbmurineα-myosin heavy chain (α-MHC) promoter (a gift from J. Robbins,
Children's hospital, Cincinnati, OH). This transgenic unit was subcloned into a
pBluescript-based vector. The linear transgene fragments were released from
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transgene was injected into pronuclei of fertilized mouse oocytes by the
Transgenic Core at University of Cincinnati.
1.3. Southern blot, Northern blot, and RT-PCR analyses
Southern blot analysis was performed to screen the transgenic mice. Ten μg
of genomic DNA prepared from tail biopsies was digested with EcoRI and
electrophoresed. The blots were hybridized with the SalI to SalI fragment of the
released transgene and visualized on PhosphorImager (Amersham biosciences,
Piscataway, NJ. USA).
In Northern blot analysis, total RNA was isolated from heart using TriZol
(Invitrogen, San Jose, CA, USA). 30 μg of total RNAwere was fractionated by
1% formamide gel and blotted onto Hybond-N+ nylon membranes (Amersham
biosciences, Piscataway, NJ, USA). Blots were hybridized with 25 ng of 32P-
labeled probe in QuikHyb solution (Stratagene, La Jolla, CA, USA) at 65 °C for
1 h, sequentially washed with 2× SSC, 0.1% SDS and 0.1× SSC, 0.1% SDS. The
blot was exposed to a phosphorscreen and analyzed on the Amersham
biosciences PhosphorImager (Amersham biosciences, Piscataway, NJ, USA).
RT-PCR reaction was performed using SuperScript III kit (Invitrogen, San
Jose, CA, USA). Five micrograms of total RNA from wild type and NLS-AIP4
hearts were used for reverse transcription. One tenth of the cDNA synthesized
was used as template for the PCR reaction. Primers and their nucleotide
sequences are listed below:
GAPDH sense primer: 5-AACGGATACATTGGGGGTAG-3′
GAPDH antisense primer: 5-CATGGAGAAGGCTGGGGCTC-3′
ANF sense primer: 5′-GAAGACCCCAAGGACTTTCC-3′
ANF antisense primer: 5′-GCAGTGCAGCTTTTTCCTTT-3′
β-MHC sense primer: 5′-CTCCCAAGGAGAGACGACTG-3′
β-MHC antisense primer: 5′-CCCTTGGTGACGTACTCGTT-3′
1.4. Surgical modes
Alzet miniosmotic pumps (no. 2002; Alza Corp., Mountain View, CA, USA)
containing ISO (60 mg/kg/day) were surgically inserted dorsally and
subcutaneously in wild type and NLS-AIP4 mice under isoflurane anesthesia.
All mice were sacrificed 2 weeks later and the heart and body weights were
measured.
1.5. Heart isolation and Langendorff perfusion
All animal procedures were performed in accordance with the Guide for the
Care and Use of Laboratory Animals published by the US National Institutes of
Health and were approved by the IACUC of the University of Cincinnati.
Three- to 4-month-old FVB/N wild type and NLS-AIP4 mice were
anesthetized and their hearts rapidly excised. The aorta was cannulated with a
20-gauge cannula and perfused retrogradely at a pressure of 80 mm Hg with
Krebs–Henseleit bicarbonate-buffered saline (25 mM NaHCO3, 118 mM NaCl,
4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM KH2PO4, 1.28 mM MgSO4, 0.5 mM
EDTA, pH 7.3–7.4 at 37 °C) supplemented with 10 mM glucose and
equilibrated with 95% O2, 25% CO2. The buffer was filtered through a 1 μm
micro-filter (Radnoti, Colorado Springs, CO, USA). The temperature of the
perfusates and hearts were maintained at 37 °C by the use of a water-jacketed
apparatus, monitored and recorded on the 4S PowerLab (AD Instruments,
Colorado Springs, CO, USA). A polyethylene (PE-50) catheter was inserted
through the left atrium and pulled through the left ventricle at the apex. The
distal end was connected to the pressure transducer and the left ventricle
pressure recorded on the 4S PowerLab System. Immediately above the aortic
cannula, a pressure transducer was connected to record the perfusion pressure on
the 4S PowerLab System.
All hearts were perfused for a 20-min equilibration period before ISO
(10−8 M) and ET-1(10−8 M), were infused for a period of 10 min. Saline
solution was used in the control group. All drugs were added by infusion pump
through an injection port directly above the aortic cannula. Three hearts were
used for each condition. At the end of the perfusion, hearts were quickly frozen
in dry ice and stored at −80 °C.1.6. Cytoplasmic and nuclear protein fraction isolation
Nuclear and cytoplasmic protein fractions of perfused hearts were obtained
using NE-PER nuclear and cytoplasmic extraction reagents (Pierce, Rockford,
IL) according to the manufacturer's protocol. Briefly, frozen hearts were
homogenized for 10 s on ice (repeated four times) in ice-cold CER I buffer (at
ratio of 50 mg/ml) containing protease and protein phosphotase inhibitors. The
homogenates were incubated on ice for 10 min, and then CER II (55 μl/ml of
CRE I buffer used) were added and mixed by vortexing for 5 s. Samples were
centrifuged for 5 min at 4 °C at 14,000×g, and the supernatants were collected as
the cytoplasmic extracts. The pellets were resuspended in nuclear extraction
reagent, NER, (500 μl/ml of CRE I buffer used) containing protease and
phosphotase inhibitors, and incubated on ice for a total of 40 min with vortexing
at 10-min intervals. The sample was then centrifuged for 10 min at 4 °C at
16,000×g and supernatants collected as nuclear extracts. The cytoplasmic and
nuclear fractions were stored at −70 °C.
1.7. Western blot
SDS sample buffer was added to the cytoplasmic or nuclear fractions, which
were then denatured for 5 min at 95 °C. An equal volume from each sample was
resolved on an SDS-polyacrylamide gel by electrophoresis, and then transferred
electrophoretically onto nitrocellulose membranes. Western blots were per-
formed according to the manufacturer's instructions. The bands were detected
using ECL with X-ray films.
1.8. Immunohistochemistry
Mouse hearts were perfused with cold phosphate-buffered saline (pH 7.4)
for 15 s via the abdominal aorta, followed by cold 10% buffered formalin.
Individual tissues were removed and postfixed by immersion in 10% buffered
formalin for 48 h followed by 70% ethanol. The tissue was embedded in paraffin
and 4-μm sections cut. The Vectastain ABC Peroxidase Elite IgG kit with
diaminobenzidine substrate (Vector Laboratories, Burlingame, CA) was used to
detect antigen–antibody complexes. The sections were counterstained with
hematoxylin.
2. Results
2.1. Characterization of NLS-AIP4 transgenic mice
NLS-AIP4 transgenic mice were identified by Southern blot
analyses (Fig. 2A). Significant amounts of AIP4 message were
expressed in NLS-AIP4 mouse heart in Northern blot analyses
(Fig. 2B). To confirm the localization of AIP4 expression in
cardiomyocyte nuclei, immunohistochemistry analyses were
performed. The tissue sections from NLS-AIP4 hearts using
anti-AIP antibody showed that the AIP4 protein was highly
concentrated in the nucleus (Fig. 2C). Furthermore, by using
isolated nuclear and cytosolic fractions from wild type and
NLS-AIP4 heart homogenates, Western blot analysis demon-
strated that the AIP was exclusively expressed in nuclear
fraction of transgenic mice (Fig. 2D).
2.2. Nuclear expression of AIP4 does not affect
phosphorylation of phospholamban
PLN is regulated by phosphorylation of Thr17 by cyto-
plasmic CaMKIIδC and of Ser16 by PKA [23–25]. To evaluate if
the nuclear-targeted expression of AIP4 affects PLB phosphoryla-
tion, the PLB phosphorylation levels under either basal or sti-
mulated conditions were examined using Langendorff perfusion.
Fig. 4. Cardiac nuclear CaMKII signaling. (A) A schematic nuclear CaMKII
pathway. ET-1 acts through G-protein-coupled receptors to activate CaMKII,
which in turn phosphorylates CREB, NFkB, and HDAC. HDAC, histone
deacetylase; IP3, inositol 1,4,5-trisphosphate; IP3R, IP3 receptor. (B) Western
blot analyses of CREB and NFκB phosphorylation. Cytoplasmic and nuclear
extracts from wild type and NLS-AIP4 hearts were subjected to SDS/PAGE and
immunoblotted with anti-phospho-NFκB-S536, anti-phospho-CREB-S133, or
anti-total CREB antibodies. (C) Analyses of HDAC5 translocation. Nuclear
extracts from wild type and NLS-AIP4 hearts were subjected to SDS/PAGE and
immunoblotted with anti-HDAC5 total antibody. Bands were scanned and
quantified using AlphaEaseFC software [Alpha Innotech Co., (San Leandro,
Fig. 2. Characterization of NLS-AIP4 transgenic mice. (A) Southern blot ana-
lyses of tail DNA from transgenic founders. The samples were digested with
EcoRI and hybridized with the SalI to SalI released fragment (Fig. 1B) as
probe. (B) Northern blot analyses of total RNA isolated from wild type and
NLS-AIP4 mice using the SalI to SalI released fragment as probe. (C)
Immunohistochemistry of a NLS-AIP4 mouse heart section using anti-AIP
antibody. (D) Western blot analyses of AIP4 expression. Cytoplasmic and
nuclear extracts from wild type and NLS-AIP4 mouse hearts were subjected to
SDS/PAGE, and electroblotted and probed anti-AIP antibody.
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PLN in NLS-AIP4 mice was not significantly altered under basal
or ISO (10−8 M) stimulated conditions. Our results indicate that
functional expression of AIP4 is exclusively in the nucleus
without affecting the cytoplasmic events.
2.3. Cardiac nuclear CaMKII signaling
CaMKII has been shown a kinase that phosphorylates CREB
[14], NFκB [26], and HDAC [21] (Fig. 4A). To examine the
transcription factor targets of cardiac nuclear CaMKII, Langen-
dorff perfusion analyseswere performed.Western blot analyses of
the perfused hearts showed that phosphorylation of CREB-S133
and NFκB-S536 was not achieved when stimulated with ET-1
(10−8 M) (Fig. 4B) suggesting that cardiac nuclear CaMKII does
not affect transcription events involving CREB or NFκB.
Class II HDACs have been shown to be involved in
cardiac hypertrophy [27]. Phosphorylation of HDAC by
CaMKII and other protein kinase(s) causes their translocation
from the nucleus to cytoplasm, which releases the inhibitory
effect on MEF2 transcription activity. Active MEF2 transcrip-
tion then leads to hypertrophy. Perfused wild type and NLS-Fig. 3. Phospholamban phosphorylation status in wild type and NLS-AIP4
mouse hearts. Cytoplasmic and nuclear extracts were subjected to SDS/PAGE
and immunoblotted with anti-PLN-Ser16 and Thr17 antibodies.
CA, USA)].AIP4 mouse hearts were stimulated with ET-1 to evaluate if
cardiac nuclear CaMKII promotes HDAC translocation.
Western blots using anti-HDAC5 antibody in nuclear fraction
from wild type and NLS-AIP4 hearts showed that HDAC is
retained in the NLS-AIP4 mouse heart nuclei (Fig. 4C). These
results suggest that cardiac nuclear CaMKII is involved in
HDAC5 translocation.
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hypertrophy under physiological stress
NLS-AIP4 mice heart growth was significantly retarded until
15 wk of age (Fig. 5A and B). The hearts of NLS-AIP4 mice are
∼20% smaller than that of wild type mice. However, age
(8 months) and pregnancy cause an increase in heart size (Fig.
5A and B), systemic edema, sedentariness, and morbidity in
NLS-AIP4 mice. Semi-quantitative RT-PCR analyses of hyper-
trophic marker genes in pregnancy-stressed animals show that
the message level of ANF and β-MHC increased in the heart ofFig. 5. Inhibition of nuclear CaMKII activity affects heart growth and induces
hypertrophy when mouse are physiologically stressed. (A) Representative
images of whole hearts. (B) Average heart weight of wild type and NLS-AIP4 at
3-week (n=18 for each group), 8-week (n=10 for each group), 15-week (n=11
for each group), and 8-month-old (n=3 for each group). (C) Semiquantitative
RT-PCR of ANF and β-MHC mRNA levels in the hearts of pregnant wild type
and NLS-AIP4 mice. GAPDH gene was used as a control.
Fig. 6. Stimulus-induced cardiac hypertrophy. Heart-to-body ratios were deter-
mined after isoproterenol infusion (60 mg/kg/day) over 14 days in wild type and
NLS-AIP4 animals (n=12 for each group). Control groupmice were infusedwith
normal saline.NLS-AIP4 animals (Fig. 5C), indicating that hypertrophic events
occur in NLS-AIP4 mice when they are under physiological
stress.
2.5. Inhibition of nuclear CaMKII activity does not attenuate
ISO induced cardiac hypertrophy
The NLS-AIP4 mouse was evaluated for the development of
stimulus-induced hypertrophy. Three-month-old wild type and
NLS-AIP4 mice were implanted with Alzet miniosmotic pumps
containing saline or ISO (60 mg/kg/day). These mice had a
similar increase in heart-to-body weight ratios (∼30% in wild
type mice and ∼31% in NLS-AIP4 mice) after a 2-week ISO
application (Fig. 6). The result indicated that inhibition of
nuclear CaMKII activity does not modify development of the
stimulus-induced hypertrophy.
3. Discussion
The functional relevance of subcellular localization of
CaMKII in cardiomyocytes is not understood. In this study, we
utilized the α-MHC promoter and a NLS signal to target the
expression of a potent CaMKII inhibitory peptide, AIP, into
cardiomyocyte nucleus. This approach provides rationale to
study the function of subcellular CaMKII in the heart. Che-
mical inhibitors of CaMKII, KN-62 and KN-93, globally
disrupt cellular function by inhibiting CaMKII in all regions
of the cell. Gene disruption and siRNA techniques used to
“knockdown” a selective CaMKII isoform also affects the
entire cell. The advantage of utilizing inhibitory peptides to
define the role of CaMKII is that specific cell expression can be
controlled by the appropriate gene promoter, and intracellular
localization can be directed through the use of cellular targeting
sequences.
In the present report, we targeted expression of AIP to the
cardiomyocyte nucleus. Furthermore, we assessed a HDAC5
translocation from nucleus to cytoplasm was reduced indicating
that the expressed AIP4 is functional in the nucleus. On the other
hand, though it has been shown in many tissues that nuclear
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[26] phosphorylation, our study demonstrates that cardiac
nuclear CaMKII is not involved in regulating CREB and NFκB
promoted transcription.
Transgenic mice overexpressing nuclear CaMKIIδB causes
cardiac hypertrophy, ventricular dilation, and decreased con-
tractile function [28]. In their mouse model decreased PLN
phosphorylation at both Thr17 and Ser16 were observed.
However, in our NLS-AIP4mice inhibition of nuclear CaMKIIδ-
B activity does not lead to a decrease in PLN phosphorylation at
Thr17 and Ser16, indicating inhibition of nuclear CaMKII
activity does not affect sarcoplasmic events involving phospho-
lamban regulated by cytoplasmic CaMKIIδC and PKA in the
cytoplasm.
Growth of the hearts in NLS-AIP4 mice was significantly
retarded until 15 weeks of age, which suggests that nuclear
CaMKIIδB involves postnatal heart development. Ca
2+, acts as
a major second messenger in directing the fate of stem cells and
patterning the heart in the embryo, has been shown to play an
important role in cardiac cell differentiation and heart develop-
ment [29]. Wnt-Ca2+ signaling mediated through CaMKII
involves in cardiogenesis was discovered in vertebrate (Xeno-
pus) [30,31]. Wnts are a large family of secreted signaling
molecules that are involved in diverse developmental process
including cell differentiation, cell migration, cell polarity, and
cell proliferation. The Wnt-β-catenin pathway activates intra-
cellular protein Dishevelled (DsH) through Frizzled (Fz)
receptors, leading translocation of β-catenin into the nucleus
to activate transcription of target genes. Sheldahl et al. [30] and
Kuhe et al. [31] showed that the Wnt-β-catenin pathway also
stimulates intracellular Ca2+ release and activates Ca2+/
calmodulin-dependent CaMKII. Disruption of the Wnt-Ca2+
pathway leads to embryos with reduced or missing heart [30].
Their study indicated the role of CaMKII in cariogenesis in
vertebrate. However, how CaMKII affects mammalian adult
cardiac myocyte growth has not defined. Our study clearly
suggests that CaMKII plays an important role in postnatal heart
development. Luo et al. [32] showed that PI3K signaling
regulates cardiac cell growth and organ size. Class IA
phosphoinositide 3-kinases (PI3Ks) regulate cell growth and
organ size. Mice that have muscle-specific deletion of subunits
of PI3K have attenuated Akt signaling in the heart, reduced
heart size, and altered cardiac gene expression. Therefore, the
possible link between nuclear CaMKII and PI3K signaling
requires further investigation.
In response to increased workload, the adult heart grows
due to an increase in the size of individual cardiomyocytes. In
diseased states, the chronic increase in workload leads to patho-
logical hypertrophy of the heart. In our study, aging or preg-
nancy-stressed NLS-AIP4 mice increased heart size and
expression of hypertrophic genes. These results suggest that
the absence of adequate Ca2+ signaling through nuclear CaMKII
regulated pathways leads to the development of cardiac disease.
In ISO induced hypertrophy, lose of nuclear CaMKII activity did
not promote hypertrophy when compared to wild type animals,
suggesting that nuclear CaMKII induced hypertrophy is inde-
pendent of β-adrenergic signaling.In summary, our study demonstrated that inhibition of
cardiac CaMKIIδB activity results in reduced rate of heart
growth in young animals and induces hypertrophy in aged or
pregnancy-stressed animals. The hypertrophy does not appear
to involve transcription factor CREB and NFκB.
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